Recent corporate updates from Orchestra BioMed Holdings highlight financial reporting disclosures for the second quarter, noting modest product revenues, widened net losses driven by increased research and development expenditures, and a strengthened balance sheet backed by approximately $110 million in cash, cash equivalents, and marketable securities. Additionally, the company announced that its pivotal BACKBEAT clinical trial evaluating AVIM therapy remains firmly on track, received a second FDA Breakthrough Device Designation for hypertension patients requiring pacemakers, and joined the Russell 2000 and Russell 3000 indexes.